A Pharmacokinetic, Pharmacodynamic, Safety Study With AOP LDLA202, ONO LDL50 and Esmolol in Healthy Volunteers

Inclusion Criteria: * Male and female human subjects, age 18-45 years, Caucasians * Body weight of at least 50 kg, maximum of 90 kg. Body-mass index 18.5 to 30.0 kg/m2. * Subjects without clinically relevant abnormalities as determined by baseline medical history, physical examination, blood pressure, heart rate and ear temperature at screening. * Subjects without clinically relevant abnormalities as determined by blood count, coagulation tests, biochemistry, infectious disease screening, urinalysis, ECG, and 2D Echo at screening. * Subject is willing and able to undergo procedures required by this protocol and gave written informed consent. * Agreeing to not using any prescription and over the counter medications * No history or presence of alcoholism or drug abuse Exclusion Criteria: * Subjects with history or presence of clinically relevant cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological, metabolic, hematological, gastrointestinal, endocrine, immunological, psychiatric or skin diseases. * Subjects with bradycardia (heart rate below 50 bpm), tachycardia (heart rate above 100 bpm), hypotension (systolic blood pressure below 100 mmHg, and/or diastolic blood pressure below 70 mm Hg) at screening, history of clinically relevant arrhythmias. * Subjects with clinically relevant cardiac supraventricular or ventricular arrhythmias. * Subjects with atrioventricular block of grade II and III, sick sinus syndrome, sinoatrial block or congestive heart failure. * Participation in a clinical drug study or bioequivalence study 60 days prior to present study. * History of malignancy or other serious diseases. * Any contraindication to blood sampling. * History of i.v. drug abuse. * Subjects with positive HIV tests, HBsAg or Hepatitis C tests or other acute, subacute or chronic infectious disease. * Known history of hypersensitivity to any IMP. * Refusal to abstain from smoking or consumption of tobacco products 48 hours before drug administration and during the study period. * Refusal to abstain from alcohol, caffeine, or other xanthines, or grapefruit containing food or drinks for 72 hours before drug administration and during the study period. * Refusal to abstain from strenuous activities for 7 days before screening and end-of-study examinations, before and during each study period. * Subjects with anomalies of the venous and arterial vessels of the forearms or systemic vascular diseases. * Pregnancy and/or breast-feeding.